Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Peptide Regulatory Tracker: FDA Status and Compounding Lists

This tracker shows where 29 peptides stand with the FDA. It covers every peptide on this site with a dated FDA status record: approvals, withdrawals, label changes, clinical development and compounding list positions, each checked against FDA and ClinicalTrials.gov records. Each row gives the US status, the approved products behind it, and the peptide's position on FDA's compounding lists, dated to the FDA document it comes from. It also lists all 35 FDA-approved peptides on this site, plus 3 whose approval FDA withdrew, with the FDA applications behind them.

29 peptides trackedChecked 52 source documents archived

Peptide Schedule Research TeamReviewed Oct 15, 2026

It depends on the peptide. FDA records from Oct 10, 2026 show 35 peptides on this site with a current FDA approval; 33 still have a product doctors can prescribe. Another 111 peptides and related compounds here have no FDA-approved product.

Prescription examples include semaglutide and tirzepatide. The full list is below. At each maker's request, FDA has withdrawn the approvals of enfuvirtide (Fuzeon), nesiritide (Natrecor) and sermorelin (Geref).

Under section 503A, a pharmacy can compound from a bulk substance only if one of three things is true. It has a USP or NF monograph, it is part of an FDA-approved drug, or it is on FDA's 503A bulks list. Substances nominated for that list sit in interim categories while FDA reviews them. FDA's interim policy says it does not intend to act against pharmacies using Category 1 substances, if other conditions are met. Category 2 holds substances FDA says raise significant safety risks, and the policy does not cover them. Outsourcing facilities under 503B follow a separate list.

Peptides sold "for research use only" are not approved for use in people. This section covers FDA status only. State laws and other countries differ, and it is not legal advice.

Pending FDA Decisions

Waiting on an FDA rule, no date set

FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed these 7 peptides on July 23 and 24, 2026. Pharmacy compounding of any of them needs an FDA rule adding it to the 503A bulks list first. No date is set.

Discussed
Discussed
Next review by end of Feb 2027

FDA intends to consult PCAC on these (FDA's 503A categories list, FDA's PCAC meeting page). No meeting date is set yet.

A committee vote is advice to FDA, not a rule. A Federal Register search on found no proposed or final FDA rule on the 503A bulks list since .

Sources: Federal Register 2026-07361, the meeting notice () · FDA briefing on BPC-157 · FDA briefing on TB-500 · FDA briefing on Epithalon · FDA meeting page.

Get an alert when FDA rules on BPC-157, TB-500 and 5 more

Follow every legal or FDA change, these 7 included. By default, alerts come as one weekly push that names the peptides.

At a Glance

Browse all approved peptides by goal, with what the research and users say about each, in the FDA-approved peptides list.

12 Peptides Left Category 2 in April 2026

FDA's 503A categories list, current as of , shows the nominations for 12 peptides as withdrawn by their nominators: BPC-157, TB-500, Epithalon, GHK-Cu, MOTS-c, Melanotan II, KPV, LL-37, Semax, DSIP, Dihexa and PEG-MGF. They were in Category 2, the group FDA says raises significant safety risks. Leaving Category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026). FDA's Pharmacy Compounding Advisory Committee discussed 7 of them on July 23 and 24, 2026 (FDA meeting page). A committee vote is not an FDA rule. Show them in the tracker. What leaving Category 2 means.

FDA Status Records: 29 Peptides

Download CSV

Peptides with a dated FDA status record: 9 FDA-approved, 2 in clinical development and 18 not approved in the US.

  • 503A: 12 peptides with the nomination withdrawn, in no category
  • 503A: 1 peptide in Category 1, under evaluation
  • 503B: 3 peptides that FDA proposed not to include
US status
Compounding

Showing 29 peptides

FDA-approved (9)

In clinical development (2)

  • CagriSemaIn clinical development
    Weight loss

    Research says: Phase 3 REDEFINE program confirms 22.7% body weight loss (efficacy estimand, REDEFINE 1) in obesity without T2D at 68 weeks. Key study: REDEFINE 1.

    Users say: High interest driven by trial data. Actual grey-market access requires DIY stacking of separate research-grade cagrilintide + semaglutide.

    Compounding lists
    No entry on FDA's 503A or 503B lists in the captured documents
    Sources
    ClinicalTrials.gov NCT05669755 (saved Oct 7, 2026) · ClinicalTrials.gov NCT07357766 (saved Oct 6, 2026)Checked
  • RetatrutideIn clinical development
    Weight loss

    Research says: TRIUMPH-1 (NEJM 2026, n=2,339) reported 25.0% mean body weight reduction at 80 weeks on 12 mg, counting everyone randomized. Key study: TRIUMPH-4 Phase 3.

    Users say: Referred to as "Godzilla" and "Triple G" in weight-loss communities.

    Compounding lists
    No entry on FDA's 503A or 503B lists in the captured documents
    Sources
    ClinicalTrials.gov NCT07629401 (saved Oct 6, 2026)Checked

Not approved in the US (18)

FDA Applications Behind Each Approved Peptide

In all, 35 peptides on this site have at least one FDA approval. Of those, 33 still have a product a doctor can prescribe, listed with prescription status in FDA's records (1 only inside a combination product). The other 2 are approved, but every product listed is discontinued. The table also lists 3 peptides whose approvals FDA withdrew, each with its Federal Register notice: enfuvirtide (Fuzeon), nesiritide (Natrecor) and sermorelin (Geref). Each application links to the FDA record saved on this site. To browse them by goal, use the FDA-approved peptides list.

PeptideFDA-approved productsFirst dated approvalFDA status
Acthar NDA 007504 (corticotropin), discontinuedActhar Gel / Acthar Gel (Autoinjector) NDA 008372 (corticotropin)Purified Cortrophin Gel NDA 008975 (corticotropin)Cortrosyn NDA 016750 (cosyntropin)1950Prescription (some products discontinued)
Angiomax NDA 020873Angiomax RTU NDA 211215Bivalirudin in 0.9% Sodium Chloride NDA 208374, discontinued2000Prescription (some products discontinued)
Calcimar NDA 017769 (calcitonin salmon), discontinuedMiacalcin NDA 017808 (calcitonin salmon)Miacalcin NDA 020313 (calcitonin salmon), discontinuedFortical NDA 021406 (calcitonin salmon recombinant), discontinuedCalcimar NDA 017497 (calcitonin salmon), discontinued1978*Prescription (some products discontinued)
Kinevac NDA 017697Sincalide NDA 2108501976Prescription
DDAVP (Needs No Refrigeration) / DDAVP NDA 017922, discontinuedDDAVP NDA 018938DDAVP NDA 019955Desmoda NDA 2198731978Prescription (some products discontinued)
Trulicity BLA 1254692014Prescription (some products discontinued)
Fuzeon NDA 021481, approval withdrawn 2026 (91 FR 41045)2003Approval withdrawn in 2026
Integrilin NDA 020718, discontinuedEptifibatide ANDA 0908541998Prescription (some products discontinued)
Byetta NDA 021773, discontinuedBydureon Pen / Bydureon NDA 022200, discontinuedBydureon BCise NDA 209210, discontinuedExenatide Synthetic ANDA 2066972005Prescription (some products discontinued)
Glucagon NDA 012122 (glucagon hydrochloride), discontinuedGlucaGen NDA 020918 (glucagon hydrochloride), discontinuedBaqsimi NDA 210134 (glucagon)Gvoke Kit / Gvoke HypoPen / Gvoke PFS / Gvoke VialDx NDA 212097 (glucagon)1960Prescription (some products discontinued)
Factrel NDA 018123 (gonadorelin hydrochloride), discontinuedLutrepulse Kit NDA 019687 (gonadorelin acetate), discontinued1982Discontinued
Pregnyl BLA 017692, NDA until 2020Novarel BLA 017016, NDA until 2020Chorionic Gonadotropin BLA 017067, NDA until 2020A.P.L. BLA 017055, NDA until 2020, discontinued1973*Prescription (some products discontinued)
Humatrope BLA 019640, NDA until 2020Genotropin BLA 020280, NDA until 2020Norditropin BLA 021148, NDA until 2020Omnitrope BLA 021426, NDA until 20201986*Prescription (some products discontinued)
Firazyr NDA 0221502011Prescription
Somatuline Depot NDA 022074Lanreotide Acetate NDA 2153952007Prescription
Lupron NDA 019010 (leuprolide acetate), discontinuedLupron Depot NDA 019732 (leuprolide acetate)Eligard Kit NDA 021343 (leuprolide acetate)Camcevi Kit NDA 211488 (leuprolide mesylate)1985Prescription (some products discontinued)
Linzess NDA 2028112012Prescription
Victoza NDA 022341Saxenda NDA 206321Liraglutide ANDA 2155032010Prescription
Adlyxin BLA 208471, NDA until 2020, discontinuedSoliqua 100/33 BLA 208673, NDA until 2020, combination with insulin glargine2016Prescription, in combination only
Scenesse NDA 2107972019Prescription
Natrecor NDA 020920, approval withdrawn 2020 (85 FR 28950)2001Approval withdrawn in 2020
Sandostatin NDA 019667Sandostatin LAR NDA 021008Mycapssa NDA 208232Bynfezia Pen NDA 2132241988Prescription (some products discontinued)
Pitocin NDA 018261Syntocinon NDA 018245, discontinuedSyntocinon NDA 012285, discontinued1980*Prescription (some products discontinued)
Signifor NDA 200677 (pasireotide diaspartate)Signifor LAR Kit NDA 203255 (pasireotide pamoate)2012Prescription
Trulance NDA 2087452017Prescription
Symlin NDA 021332, discontinued2005Discontinued
Vyleesi (Autoinjector) NDA 2105572019Prescription
Nplate BLA 1252682008Prescription
Ozempic NDA 209637Ozempic / Rybelsus NDA 213051Wegovy / Wegovy HD / Wegovy FlexTouch NDA 215256Wegovy NDA 2183162017Prescription (some products discontinued)
Geref NDA 019863, approval withdrawn 2009 (74 FR 23407)Geref NDA 020443, approval withdrawn 2009 (74 FR 23407)1990Approval withdrawn in 2009
Imcivree NDA 2137932020Prescription
Forzinity NDA 2152442025Prescription
Gattex Kit NDA 2034412012Prescription
Egrifta / Egrifta SV / Egrifta WR BLA 022505, NDA until 20202010Prescription (some products discontinued)
Mounjaro / Mounjaro KwikPen / Mounjaro (Autoinjector) NDA 215866Zepbound / Zepbound KwikPen / Zepbound (Autoinjector) NDA 2178062022Prescription
Trelstar NDA 020715Triptodur Kit NDA 2089562000Prescription
Pitressin Tannate NDA 003402 (vasopressin tannate), discontinuedVasostrict NDA 204485 (vasopressin)Vasopressin NDA 212593 (vasopressin)Vasopressin in Sodium Chloride 0.9% NDA 217569 (vasopressin)2014*Prescription (some products discontinued)
Prialt NDA 0210602004Prescription (some products discontinued)

* FDA's records show this ingredient was approved or sold before that year: either an older application with no date, or a first dated approval that FDA does not class as a new ingredient. For Humatrope, FDA's 2020 transition list says March 8, 1987, while Drugs@FDA and the Purple Book say October 16, 1986.

The table shows key applications for each peptide, including a generic where no brand is still sold. It is not every application FDA holds.

The list follows this site's catalog, which includes some protein hormones and fusion proteins that FDA licenses as biologics (BLAs). Applications marked "NDA until 2020" were drug applications that were deemed biologics licenses on March 23, 2020, as the law required for proteins, per FDA's transition list.

Also FDA-approved but not peptides, so not listed: TRT (Testosterone Replacement Therapy), L-Carnitine, Orforglipron.

Records: Drugs@FDA through openFDA as of , and for biologics the FDA Purple Book as of September 2026. Retrieved .

Recent Regulatory Changes

  1. Regulatory

    FDA added a major adverse cardiovascular event risk indication in type 2 diabetes to Mounjaro (S-044, S-045) on Aug 27, 2026, per the updated FDA label.

    What this does not mean: SURPASS-CVOT showed noninferiority to dulaglutide, not superiority. Zepbound did not gain this indication.

    Peptides: Tirzepatide

    Source: Mounjaro (tirzepatide) prescribing information (openFDA label record, SPL version 40, effective Aug 27, 2026) (opens in a new tab) · Saved copy

  2. Regulatory

    PCAC backed Semax for the 503A bulks list 8-5-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: Semax

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  3. Regulatory

    PCAC recommended epitalon for the 503A bulks list on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: Epithalon

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  4. Regulatory

    PCAC did not back emideltide (DSIP) for the 503A list 6-7-1 on Jul 24, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote is advice to FDA, not a decision. Emideltide stays off the 503A bulks list unless FDA adds it by notice-and-comment rule.

    Peptides: DSIP

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  5. Regulatory

    PCAC backed TB-500 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: TB-500

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  6. Regulatory

    PCAC backed MOTS-c for the 503A bulks list 7-5-2 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: MOTS-c

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  7. Regulatory

    PCAC backed KPV for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: KPV

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

  8. Regulatory

    PCAC backed BPC-157 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.

    What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).

    Peptides: BPC-157

    Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy

The full dated record, including the site's own corrections, lives on the changes page.

What the Terms Mean

  • FDA-approved. At least one product containing the peptide has an FDA approval. The tracker names the application behind it.
  • Approval withdrawn. FDA withdrew the approval, so no approved product is left. A maker can ask for this once a product is no longer sold. The tracker cites the Federal Register notice for each withdrawal.
  • In clinical development. A company is testing the peptide in human trials, and no product is approved yet.
  • Not approved in the US. No FDA-approved product exists and no company-sponsored US development is recorded.
  • 503A and 503B. 503A covers pharmacies that compound for individual prescriptions. 503B covers outsourcing facilities. FDA keeps separate lists of the bulk substances each may use.
  • Category 1. FDA is still evaluating the substance for the 503A bulks list.
  • Category 2. FDA says the substance raises significant safety risks.
  • Nomination withdrawn. The people who nominated the substance withdrew the nomination, so FDA lists it in no category.
  • Proposed not to include. FDA has proposed leaving the substance off the 503B bulks list.

How This Tracker Is Built

Every value comes from an FDA document saved on this site: Drugs@FDA records, FDA drug labels, FDA's 503A categories list and 503B bulks list, and the Federal Register. The source links on each row open those saved copies, so a value still reads the same if FDA moves the original page.

The approvals listed are the FDA applications captured as sources for each row, not every approved product containing the peptide. Compounding dates are the version date of the FDA document, not the day a position began, which FDA often does not state. Each row also shows the day the values were last checked.

The FDA-approved list comes from Drugs@FDA, read through openFDA, and from FDA's Purple Book for products licensed as biologics. Each application links to the FDA response saved on this site.

Status for the other 121 peptides on this site is on each peptide's own page. A peptide joins this tracker when its FDA status is checked against FDA and ClinicalTrials.gov records and dated, and every change is logged on the changes page. How much human research backs the peptides without FDA approval is in the peptide evidence gap study.

This page is general information about regulatory status, not legal or medical advice.

Peptide Legal Status: Common Questions

Are peptides legal?

It depends on the peptide. FDA records from Oct 10, 2026 show 35 peptides on this site with a current FDA approval; 33 still have a product doctors can prescribe. Another 111 peptides and related compounds here have no FDA-approved product. Pharmacies can compound a peptide only with a USP or NF monograph, as part of an approved drug, or from FDA's 503A bulks list. Substances nominated for that list sit in interim categories while FDA reviews them. FDA's interim policy says it does not intend to act against pharmacies using Category 1 substances, if other conditions are met.

Can I legally buy peptides?

A peptide with an FDA-approved product is legal to get with a prescription. 33 peptides on this site still have a product doctors can prescribe, per FDA records from Oct 10, 2026. Peptides sold "for research use only" are not approved for use in people. Compounding follows FDA's 503A and 503B rules, and state laws differ; this page is not legal advice and names no sellers.

What is Category 2?

Category 2 is FDA's interim group for nominated 503A bulk substances that it says raise significant safety risks. FDA's interim compounding policy covers Category 1 substances, not Category 2. 12 peptides on this site left Category 2 when their nominations were withdrawn, per FDA's 503A list current as of Apr 22, 2026.

Is BPC-157 FDA approved?

No. BPC-157 has no FDA-approved product. FDA's 503A categories list, current as of Apr 22, 2026, shows its nomination as withdrawn. That took it out of Category 2 but did not add it to the 503A bulks list.

Cite or Reuse This Data

Peptide Schedule. Peptide Regulatory Tracker. Updated Oct 15, 2026. https://www.peptideschedule.com/research/peptide-regulatory-tracker

The table is licensed under CC BY 4.0 (opens in a new tab). Reuse it freely if you credit Peptide Schedule, link to this page and the license, and note any changes. Download the CSV.